BOSTON--(BUSINESS WIRE)--At the annual meeting of the Harvard Dental Alumni Association on May 30, 2014, Dean R. Bruce Donoff, DMD, MD presented the Harvard School of Dental Medicine (HSDM) Distinguished Alumnus Award to Samuel Lynch, DMD, DMSc for outstanding achievements in his field. Dr. Lynch is a 1989 graduate of the HSDM residency in Periodontology as well as the Harvard Medical School Doctorate of Medical Sciences.
The Distinguished Alumnus Award is to recognize an individual who has made significant contributions that honor the mission of the School in addition to supporting HSDM through the generosity of their time, talent, and philanthropic commitments. “Dr. Lynch embodies the HSDM spirit as reflected by his outstanding achievements throughout multiple disciplines of dentistry and medicine and his dedication to the betterment of patient health through his discoveries, dedication and talents,” said Dean Donoff. “Beyond his academic and business accomplishments, Dr. Lynch’s humanitarian commitments, as evidenced by his current medical mission trip to the underserved regions of Guatemala, embody the best of the spirit of Harvard.”
HSDM recognized Dr. Lynch for his significant body of scientific work in the fields of regenerative medicine and protein therapeutics, including high impact publications in scientific journals, commitment to translational medicine to bring discoveries in the laboratory to improvement in patient health, and his philanthropic commitments to HSDM and its mission of improving the health and well-being of local and global populations. Dr. Lynch’s discoveries have led to nearly $5 million in royalties and other payments to support Harvard’s mission.
"I am honored to be an alumnus of such a respected institution as HSDM and to be the recipient of their Distinguished Alumnus Award. To be included amongst the previous winners of this award who have set such high standards for innovation and patient care in their fields is incredibly humbling,” commented Dr. Lynch. “It takes a dedicated team to continuously work toward advancing innovative medical treatments, and I owe much of my success to the commitment and hard work of so many of my colleagues. I share this recognition with each of them.”
Dr. Lynch is the founder and past CEO and Chairman of BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development of products to promote the healing of musculoskeletal injuries and diseases. He is one of only a few scientists to make a medical discovery, and then found and lead a company from such discovery through full Food & Drug Administration (FDA) approval, commercialization and an initial public offering (IPO).